|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,060.20 INR | -0.97% |
|
-3.00% | -6.21% |
| 04/02 | IIFL Downgrades Mankind Pharma to Add from Buy, Price Target is INR2,300 | MT |
| 03/02 | Mankind Pharma Limited, Q3 2026 Earnings Call, Feb 03, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- MANKIND Stock
- Consensus Mankind Pharma Limited
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition